Results 161 to 170 of about 2,419 (196)

Formoterol fumarate + glycopyrrolate for the treatment of chronic obstructive pulmonary disease

Expert Review of Respiratory Medicine, 2016
Chronic obstructive pulmonary disease (COPD) is characterized by a high disability and increasing mortality. Bronchodilators are the cornerstone of pharmacological treatment in COPD, while therapeutic optimization with an improvement in symptoms and compliance represent the actual goals. This has led to the development of devices that combine different
D. Radovanovic, M. Mantero, G.F. Sferrazza Papa, V. Valenti, S. Aliberti, F. Di Marco, P. Santus   +6 more
openaire   +3 more sources

Inhaled beclometasone dipropionate/formoterol fumarate extrafine fixed combination for the treatment of asthma

Expert Review of Respiratory Medicine, 2016
Inhaled therapy is often considered the cornerstone of asthma management and international guidelines recommend combination therapy of inhaled corticosteroids (ICS) and long-acting-beta2-agonists (LABA) in a large proportion of asthmatic patients. The effectiveness of ICS/LABA is dependent on the correct choice of device and proper inhalation technique,
CRISAFULLI, Ernesto, Zanini, Andrea, PISI, GIOVANNA, Pignatti, Patrizia, Poli, Gianluigi, Scuri, Mario, CHETTA, Alfredo Antonio   +6 more
openaire   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Aclidinium bromide/formoterol fumarate as a treatment for COPD: an update

Expert Review of Respiratory Medicine, 2021
Introduction: Aclidinium/formoterol is a long-acting muscarinic antagonist (LAMA) and long-acting β2-agonist (LABA) dual bronchodilator used as a maintenance treatment for patients with chronic obstructive pulmonary disease (COPD). The efficacy of aclidinium/formoterol has been demonstrated consistently in patients with moderate-to-severe COPD versus ...
Anthony D, D'Urzo, Dave, Singh, James F, Donohue, Kenneth R, Chapman, Robert A, Wise   +4 more
openaire   +2 more sources

Formoterol Fumarate Inhalation Powder

Hospital Pharmacy, 2001
Each month, subscribers to The Formulary® Monograph Service receive five to six researched monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and ...
Dennis J. Cada, Terri Levien, Danial E. Baker   +2 more
openaire   +1 more source

Nebulized formoterol fumarate: Dose selection and pharmacokinetics

Pulmonary Pharmacology & Therapeutics, 2008
To determine a dose of nebulized formoterol fumarate inhalation solution (FFIS) comparable to that of the marketed formoterol fumarate dry powder inhaler (FA, 12microg), two crossover studies were conducted in subjects with COPD. Study 1 was a single-dose, double-blind, double-dummy dose-ranging study in which 47 subjects were randomly assigned to ...
Nicholas J, Gross, Edward, Kerwin, Bernard, Levine, Kenneth T, Kim, Kimberly, Denis-Mize, Mohammad, Hamzavi, Michelle, Carpenter, Mike, Rinehart   +7 more
openaire   +2 more sources

Thermodynamic Stability and Crystal Structures for Polymorphs and Solvates of Formoterol Fumarate

Journal of Pharmaceutical Sciences, 2006
Polymorph screening of formoterol fumarate was performed in 12 solvents, followed by evaluations of thermodynamic stability. Three anhydrates, a dihydrate, a diethanolate, a diisopropanolate, and a dibensylalcoholate were found. The crystal structure of three solvated modifications and of the most stable anhydrate was investigated.
K, Jarring, T, Larsson, B, Stensland, I, Ymén   +3 more
openaire   +2 more sources

Effect of formoterol fumarate treatment on exercise-induced bronchoconstriction in children

Annals of Allergy, Asthma & Immunology, 2006
Exercise-induced bronchoconstriction (EIB) is common, particularly in children.To compare the protective effect of single doses of formoterol fumarate via Aerolizer with placebo and albuterol in children with EIB.In this randomized, double-blind, double-dummy, crossover trial, 23 children (aged 4-11 years) received formoterol, 12 or 24 microg ...
David, Pearlman, Henry, Milgrom, Denise, Till, Barbara, Ziehmer   +3 more
openaire   +2 more sources

Disposition and metabolism of formoterol fumarate, a new bronchodilator, in rats and dogs

Xenobiotica, 1982
1. The disposition and metabolism of formoterol fumarate, a highly potent beta 2-adrenoceptor stimulant, were studied in rats and dogs. 2. After oral administration of [3H] formoterol fumarate to dogs, unchanged formoterol accounted for greater than 60% of the plasma radioactivity immediately after dosage; greater than 20% was due to the unchanged drug
H, Sasaki, H, Kamimura, Y, Shiobara, Y, Esumi, M, Takaichi, T, Yokoshima   +5 more
openaire   +2 more sources

Formoterol fumarate inhalation solution (Perforomist™) for COPD

Expert Review of Clinical Immunology, 2008
Formoterol fumarate is an effective treatment for chronic obstructive pulmonary disease (COPD) patients with moderate or greater severity of airflow obstruction. Published studies indicate that formoterol has a rapid onset of bronchodilation, which may enhance compliance, and sustained bronchodilation over 12 h, which produces a cumulative effect when ...
openaire   +2 more sources

Compatibility and Aerosol Characteristic of Formoterol Fumarate Mixed with Other Nebulizing Solutions

Annals of Pharmacotherapy, 2008
Background: Patients with chronic obstructive pulmonary disease (COPO) are often given admixtures of nebulizable drugs to minimize the time of administration in treatment regimens. Objective: To evaluate the physicochemical ...
Samuel, Akapo, June, Gupta, Eloisa, Martinez, Chithra, McCrea, Liwen, Ye, Mark, Roach   +5 more
openaire   +2 more sources